Parexel Execs On Global Adjustments In The Trial Site Landscape

APAC Emerges Amid Global Challenges

Senior Parexel executives tell Scrip that disruptions resulting from the Ukraine war and constraints in the US given the backlog in clinical care there could channel more trials to the Asia-Pacific region. They also discuss how things are moving in China, a market where the CRO has long-standing experience, the "conducive" ecosystem in India and issues around trial diversity.

The global trial site landscape is evolving • Source: Shutterstock

More from R&D

More from Scrip